| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A |
| Revenues: |
| Vycor Medical | 1.3 | 1.0 | 1.3 | 1.3 | | 1.3 | 0.9 | 0.9 |
| NovaVision | | | | 0.2 | | 0.2 | 0.3 | 0.4 |
| Nova Vision | 0.1 | 0.1 | 0.1 | | | | | |
| Other | | | | | | 0.0 | 0.0 | |
| Total revenues [+] | 1.4 | 1.1 | 1.4 | 1.5 | 1.4 | 1.5 | 1.2 | 1.3 |
| Products | | | | | | 1.5 | 1.1 | |
| Net interest income | | | | | | | 0.0 | |
| Revenue growth [+] | 22.0% | -18.0% | -7.7% | 9.0% | -6.8% | 27.5% | -6.8% | 12.1% |
| Vycor Medical | 22.5% | -20.0% | -0.9% | | | 42.4% | -0.8% | 23.3% |
| NovaVision | | | | | | -24.2% | -29.1% | -2.1% |
| Nova Vision | 16.5% | 10.1% | | | | | | |
| Cost of goods sold | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |
| Gross profit | 1.3 | 1.0 | 1.3 | 1.3 | 1.2 | 1.3 | 1.0 | 1.1 |
| Gross margin | 90.3% | 88.4% | 90.3% | 88.8% | 83.6% | 87.6% | 85.9% | 87.5% |
| Selling, general and administrative [+] | 1.6 | 1.7 | 1.8 | 2.2 | 2.2 | 2.6 | 2.5 | 3.4 |
| General and administrative | | | | | 2.2 | 2.6 | 2.5 | 3.4 |
| Research and development | 0.0 | | | | 0.0 | 0.0 | 0.1 | 0.1 |
| Other operating expenses | | | | | | 0.0 | 0.0 | |
| EBITDA [+] | -0.4 | -0.7 | -0.5 | -0.8 | -1.0 | -1.3 | -1.6 | -2.3 |
| EBITDA growth | -45.1% | 24.0% | -35.2% | -18.6% | -22.8% | -18.4% | -31.0% | 23.3% |
| EBITDA margin | -26.4% | -58.6% | -38.8% | -55.2% | -73.8% | -89.1% | -139.1% | -187.9% |
| Depreciation | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.2 | 0.3 | 0.3 |
| EBITA | -0.4 | -0.7 | -0.6 | -1.0 | -1.2 | -1.5 | -1.9 | -2.6 |
| EBITA margin | -30.5% | -62.6% | -42.3% | -63.6% | -83.1% | -101.1% | -162.3% | -208.3% |
| Amortization of intangibles | 0.0 | 0.0 | 0.0 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 |
| EBIT [+] | -0.4 | -0.7 | -0.6 | -1.0 | -1.3 | -1.6 | -2.0 | -2.7 |
| EBIT growth | -40.1% | 21.0% | -40.5% | -23.0% | -17.5% | -20.1% | -27.1% | 19.8% |
| EBIT margin | -31.3% | -63.7% | -43.2% | -66.9% | -94.8% | -107.1% | -170.8% | -218.5% |
| Non-recurring items [+] | | | | 0.3 | | | | |
| Asset impairment | | | | 0.3 | | | | |
| Interest expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Interest expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other income (expense), net [+] | 0.1 | -0.1 | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 | -1.3 |
| Gain (loss) on debt retirement | | | | | | | | -0.7 |
| Other non-operating income | | 0.0 | | | | | | |
| Other | | 0.0 | | | 0.0 | | -0.1 | -0.1 |
| Pre-tax income | -0.4 | -0.8 | -0.7 | -1.4 | -1.5 | -1.7 | -2.1 | -4.0 |
| Income taxes | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Earnings from continuing ops | -0.7 | -1.1 | -1.0 | -1.7 | -1.8 | -1.8 | -2.3 | -4.0 |
| Earnings from discontinued ops | 0.0 | 0.0 | -0.1 | | | | | |
| Net income | -0.8 | -1.1 | -1.1 | -1.7 | -1.8 | -1.8 | -2.3 | -4.0 |
| Net margin | -54.6% | -100.4% | -80.4% | -112.9% | -130.1% | -123.3% | -193.0% | -323.9% |
| |
| Basic EPS [+] | ($0.02) | ($0.04) | ($0.04) | ($0.08) | ($0.10) | ($0.17) | ($0.21) | ($0.39) |
| Growth | -42.6% | 3.8% | -47.4% | -19.5% | -40.8% | -20.3% | -47.3% | 2.0% |
| Diluted EPS [+] | ($0.02) | ($0.04) | ($0.04) | ($0.08) | ($0.10) | ($0.17) | ($0.21) | ($0.39) |
| Growth | -42.6% | 3.8% | -47.4% | -19.5% | -40.8% | -20.3% | -47.3% | 2.0% |
| |
| Shares outstanding (basic) [+] | 29.6 | 26.1 | 24.0 | 21.6 | 18.4 | 11.1 | 10.8 | 10.3 |
| Growth | 13.5% | 8.9% | 10.9% | 17.6% | 66.0% | 2.1% | 5.5% | 62.4% |
| Shares outstanding (diluted) [+] | 29.6 | 26.1 | 24.0 | 21.6 | 18.4 | 11.1 | 10.8 | 10.3 |
| Growth | 13.5% | 8.9% | 10.9% | 17.6% | 66.0% | 2.1% | 5.5% | 62.4% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |